Methyl Sinapate

Methyl Sinapate

SCHEMBL9908304

COC(=O)/C=C/c1cc(OC)c(O)c(OC)c1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.74
CYP3A4 P08684 1/20 0.74
CYP2D6 P10635 1/20 0.74
CYP2C9 P11712 1/20 0.74
CYP2B6 P20813 1/20 0.74
PTGS1 P23219 2/20 0.72
PKM P14618 1/20 0.72
PTGS2 P35354 1/20 0.72
EPHX2 P34913 1/20 0.69
MET P08581 6/20 0.68
ALOX5 P09917 5/20 0.68
STAT3 P40763 2/20 0.60
NFE2L2 Q16236 2/20 0.60
PTGES O14684 1/20 0.60
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
FDPS P14324 1/20 0.59
APP P05067 2/20 0.58
KDM4E B2RXH2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Sinapate SCHEMBL2517008 1.00 CYP1A2 (0.74) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL7158939 0.93 EPHX2 (0.69) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL19202508 0.92 EPHX2 (0.63) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL11210444 0.90 EPHX2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL11210454 0.90 EPHX2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL11212410 0.89 EPHX2 (0.60) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL26740971 0.89 APP (0.76) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL11212432 0.89 EPHX2 (0.60) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL30528017 0.88 CYP1A2 (0.63) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
Methyl Sinapate SCHEMBL887912 0.87 PTGS1 (0.60) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037498-A Impact-resistant plastic composite material and preparation method thereof 雄安立亚科技集团有限公司 2026-05-15 CN claimed
CN-113072602-B Phenolic acid glycosyl ester and preparation method thereof 广东省科学院化工研究所 2023-08-01 CN claimed
CN-122037498-A Impact-resistant plastic composite material and preparation method thereof 雄安立亚科技集团有限公司 2026-05-15 CN disclosed
CN-119235834-B Application of sinapic acid and derivatives thereof in preparing medicines for preventing and/or treating methamphetamine addiction withdrawal 中国药科大学 2025-10-31 CN disclosed
CN-119876216-A Bacillus subtilis expression system for producing feruloyl esterase by fermentation and application thereof 中国科学院上海高等研究院 2025-04-25 CN disclosed
CN-119235834-A Application of sinapic acid and derivatives thereof in preparing medicines for preventing and/or treating methamphetamine addiction withdrawal 中国药科大学 2025-01-03 CN disclosed
CN-119235834-A Application of sinapic acid and derivatives thereof in preparing medicines for preventing and/or treating methamphetamine addiction withdrawal 中国药科大学 2025-01-03 CN disclosed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 CN disclosed
CN-116769751-A Trifunctional enzyme Bi76 with xylanase, glucanase and feruloyl esterase activities and application thereof 广州中医药大学(广州中医药研究院) 2023-09-19 CN disclosed
CN-113072602-B Phenolic acid glycosyl ester and preparation method thereof 广东省科学院化工研究所 2023-08-01 CN disclosed
CN-116444461-A Dibenzylbutane lignan LCA derivative and application thereof 中国人民解放军海军军医大学 2023-07-18 CN disclosed
US-20110118345-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2011-05-19 US disclosed
US-20110118345-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2011-05-19 US disclosed
US-7943164-B2 Contains quercetin, myricetin and chlorogenic acid; weight loss and weight control; inhibiting glucose absorption in the gut, enhancing glucose absorption by muscle tissue, inhibiting carbohydrate transport, inhibiting glucose/fat storage and inhibiting the manufacture of glucose by the liver ATM METABOLICS, LLC 2011-05-17 US disclosed
US-7943164-B2 Contains quercetin, myricetin and chlorogenic acid; weight loss and weight control; inhibiting glucose absorption in the gut, enhancing glucose absorption by muscle tissue, inhibiting carbohydrate transport, inhibiting glucose/fat storage and inhibiting the manufacture of glucose by the liver ATM METABOLICS, LLC 2011-05-17 US disclosed
WO-2008115723-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISORDERS WITH QUERCETIN, MYRCETIN AND CHLOROGENIC ACID ATM METABOLICS LLLP (US) 2008-09-25 WO disclosed
US-20080234364-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2008-09-25 US disclosed
US-20080234364-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS ATM METABOLICS, LLC 2008-09-25 US disclosed
US-7294369-B2 Polymerisable cinnamates with lateral substitution MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2007-11-13 US disclosed
US-7294369-B2 Polymerisable cinnamates with lateral substitution MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234364-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS PNLIP, CPT1B, LIPC CYP1A2 624/4885CYP3A4 997/4885CYP2D6 677/4885
US-20110118345-A1 COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS PNLIP, CPT1B, LIPC CYP1A2 624/4885CYP3A4 997/4885CYP2D6 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.